CAR T-cell Therapy

ClinicalJuly 6, 2026

Phase I Trial of CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies

A phase I trial is investigating the efficacy and safety of CD19/CD22 CAR T cells combined with chemotherapy in children and young adults with recurrent or refractory B acute lymphoblastic leukemia.

Companies

Assets

Recent signals(6)

Phase I Trial of CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies

Phase I Trial of CAR T Cells with Chlorotoxin for MMP2+ Recurrent Glioblastoma

NCI Trials CD19/CD22 CAR T Cells for Refractory B Cell Malignancies in Young Patients

BrainChild Bio Initiates CAR T Therapy Study for DIPG Patients

Phase 2 Trial of Lisocabtagene Maraleucel Targets Minimal Residual Disease in Large B-cell Lymphoma

First-in-human Phase 1 Study of ML261 in R/R SCLC and NECs Initiated by Moonlight Bio

Upcoming catalysts

Indications

Get signals before the market moves